ZBD(SH:603567) Zheng Quan Zhi Xing·2025-07-24 16:21Core Viewpoint - The legal opinion letter from Beijing Lantai Law Firm confirms that Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. has complied with necessary legal procedures and disclosure obligations regarding the repurchase and cancellation of part of its restricted stock under the 2023 equity incentive plan [2][9]. Group 1: Decision Process and Disclosure - The company has obtained legal authorization from the board of directors to proceed with the repurchase and cancellation of restricted stocks for three former employees who have not yet lifted their sales restrictions [6]. - The company plans to repurchase a total of 144,094 shares of restricted stock at a price of 8.232 yuan per share, following the approval of relevant proposals by the board and supervisory committee [6][7]. - The company has disclosed the repurchase plan to creditors, allowing them a 30-day period to claim debts or request guarantees, with no claims reported during the disclosure period [6][7]. Group 2: Repurchase Details - The repurchase is due to the departure of three key employees, and the company will buy back the restricted stocks that have not yet been lifted from their restrictions [7]. - The total amount for the repurchase is calculated to be 1,186,181.80 yuan, sourced from the company's own funds [8]. - The company has set up a dedicated securities account for the repurchase and expects to complete the cancellation of the restricted stocks by July 29, 2025 [8].